Id |
Subject |
Object |
Predicate |
Lexical cue |
T1 |
0-103 |
Sentence |
denotes |
Lupus clinical development: will belimumab's approval catalyse a new paradigm for SLE drug development? |
T2 |
104-117 |
Sentence |
denotes |
INTRODUCTION: |
T3 |
118-224 |
Sentence |
denotes |
Systemic lupus erythematosus (SLE) is a diverse autoimmune disease affecting many different organ systems. |
T4 |
225-404 |
Sentence |
denotes |
Although disease manifestations are varied across the lupus population, the widespread presence of autoantibodies indicates that SLE immunopathology involves B-cell dysregulation. |
T5 |
405-644 |
Sentence |
denotes |
Belimumab, a human anti-B-cell activating factor (BLyS) monoclonal antibody, was invented by Human Genome Sciences and co-developed with GlaxoSmithKline and became, in 2011, the first new therapy approved for SLE patients in over 50 years. |
T6 |
645-659 |
Sentence |
denotes |
AREAS COVERED: |
T7 |
660-852 |
Sentence |
denotes |
Belimumab approval represents a milestone as a new treatment for a subset of SLE patients and also a window onto the continued unmet need for many patients suffering from this diverse disease. |
T8 |
853-1059 |
Sentence |
denotes |
This paper analyses the drugs and clinical trials of industry-sponsored development programs to profile the current SLE landscape and to consider how belimumab is shaping the future of SLE drug development. |
T9 |
1060-1075 |
Sentence |
denotes |
EXPERT OPINION: |
T10 |
1076-1273 |
Sentence |
denotes |
Our analysis demonstrates that the belimumab clinical program created a model for improvements in study designs that is reflected in ongoing clinical trials sponsored by a broad range of companies. |
T11 |
1274-1380 |
Sentence |
denotes |
Additional BLyS inhibitors, with distinctive targeting characteristics, are now in late stage development. |
T12 |
1381-1563 |
Sentence |
denotes |
A broad range of drugs with other mechanisms of action are also under investigation in Phase II - III trials, some of which are focused on the underserved lupus nephritis population. |
T1 |
0-103 |
Sentence |
denotes |
Lupus clinical development: will belimumab's approval catalyse a new paradigm for SLE drug development? |
T2 |
104-117 |
Sentence |
denotes |
INTRODUCTION: |
T3 |
118-224 |
Sentence |
denotes |
Systemic lupus erythematosus (SLE) is a diverse autoimmune disease affecting many different organ systems. |
T4 |
225-404 |
Sentence |
denotes |
Although disease manifestations are varied across the lupus population, the widespread presence of autoantibodies indicates that SLE immunopathology involves B-cell dysregulation. |
T5 |
405-644 |
Sentence |
denotes |
Belimumab, a human anti-B-cell activating factor (BLyS) monoclonal antibody, was invented by Human Genome Sciences and co-developed with GlaxoSmithKline and became, in 2011, the first new therapy approved for SLE patients in over 50 years. |
T6 |
645-659 |
Sentence |
denotes |
AREAS COVERED: |
T7 |
660-852 |
Sentence |
denotes |
Belimumab approval represents a milestone as a new treatment for a subset of SLE patients and also a window onto the continued unmet need for many patients suffering from this diverse disease. |
T8 |
853-1059 |
Sentence |
denotes |
This paper analyses the drugs and clinical trials of industry-sponsored development programs to profile the current SLE landscape and to consider how belimumab is shaping the future of SLE drug development. |
T9 |
1060-1075 |
Sentence |
denotes |
EXPERT OPINION: |
T10 |
1076-1273 |
Sentence |
denotes |
Our analysis demonstrates that the belimumab clinical program created a model for improvements in study designs that is reflected in ongoing clinical trials sponsored by a broad range of companies. |
T11 |
1274-1380 |
Sentence |
denotes |
Additional BLyS inhibitors, with distinctive targeting characteristics, are now in late stage development. |
T12 |
1381-1563 |
Sentence |
denotes |
A broad range of drugs with other mechanisms of action are also under investigation in Phase II - III trials, some of which are focused on the underserved lupus nephritis population. |